Actively Recruiting

Early Phase 1
Age: 18Years +
All Genders
ID06579248

Study of a Novel Intraoral Hypothermia Device for Preserving Taste During Radiation Therapy for Squamous Cell Carcinoma of the Larynx

Led by Henry Ford Health System · Updated on 2026-01-14

15

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Radiation therapy for head and neck cancer, especially squamous cell carcinoma of the larynx, can cause problems with taste. Researchers are studying if using a cooling device inside the mouth during radiation can help protect or reduce the loss of taste. This early phase 1 study explores the feasibility of this approach and aims to understand if cooling can lower damage to taste function caused by radiation. Participants will use an intraoral hypothermia device that circulates cooled water through the mouth while receiving combination radiation therapy and chemotherapy. The device is applied during the radiation treatments to cool the oral cavity and potentially preserve taste function. This study focuses on patients undergoing definitive treatment with chemotherapy drugs like cisplatin, carboplatin, or cetuximab, alongside radiation. During the study, participants will complete questionnaires related to taste changes, toxicity, and quality of life. Researchers will measure taste dysfunction six months after radiation therapy ends to evaluate changes. Patients will be monitored for tolerance of the device and any side effects. The total study participation includes the treatment period and follow-up assessments to assess the device's impact on preserving taste.

CONDITIONS

Brief Title

Intraoral Hypothermia Device for Preserving Taste During Radiation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients treated with combination radiation therapy and chemotherapy for locally advanced squamous cell carcinoma of the larynx
  • Age 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Able to provide informed consent and complete toxicity and quality of life questionnaires
  • Receiving chemotherapy drugs such as cisplatin, carboplatin, or cetuximab concurrently with radiation
Not Eligible

You will not qualify if you...

  • Receiving other therapies intended to reduce taste dysfunction
  • Having metastatic disease
  • Allergies or sensitivities to materials in the intraoral device
  • Prior chemotherapy or radiation therapy for head and neck cancer
  • Unable or unwilling to use or tolerate the intraoral device
  • Current or recent cigarette smokers within 3 months before treatment
  • Unable to complete required study forms (verbal completion allowed if recorded)
  • Having uncontrolled serious illnesses such as active infections needing IV antibiotics over 30 days, symptomatic heart failure, unstable angina, certain heart arrhythmias, immunocompromised state, severe liver or blood diseases, or serious psychological conditions
  • Taking medications like acetazolamide, maribavir, eszopiclone, topiramate, captopril, lithium, procainamide, terbinafine, or amiodarone without suitable substitutes during the study
  • Having baseline taste loss
  • Testing positive for COVID-19 during the study period

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Duration of radiation therapy

Participants use an intraoral hypothermia device to cool the oral cavity during radiation therapy for squamous cell carcinoma of the larynx.

Visits aligned with radiation therapy schedule

Follow-up

Duration - 6 months after radiation therapy completion

Participants are monitored for changes in taste function up to 6 months after completion of radiation therapy.

Periodic follow-up visits up to 6 months

Trial Site Locations

Total: 1 location

1

Henry Ford Health System

Detroit, Michigan, United States, 48202-2689

Actively Recruiting

Loading map...

Research Team

M

Marissa Gilbert, BSBME

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Similar Trials

Use of 18F-Fluciclovine PET to Identify Tumors in Patients W...

Brain Metastasis

Actively Recruiting

1 location

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here